+

WO2003061594A3 - Procedes et compositions destines a reduire le developpement de tolerance au medicament et/ou de dependance physique - Google Patents

Procedes et compositions destines a reduire le developpement de tolerance au medicament et/ou de dependance physique Download PDF

Info

Publication number
WO2003061594A3
WO2003061594A3 PCT/US2003/002061 US0302061W WO03061594A3 WO 2003061594 A3 WO2003061594 A3 WO 2003061594A3 US 0302061 W US0302061 W US 0302061W WO 03061594 A3 WO03061594 A3 WO 03061594A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
methods
development
reducing
compositions
Prior art date
Application number
PCT/US2003/002061
Other languages
English (en)
Other versions
WO2003061594A2 (fr
Inventor
Jennifer Whistler
Original Assignee
Univ California
Jennifer Whistler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Jennifer Whistler filed Critical Univ California
Priority to AU2003219680A priority Critical patent/AU2003219680A1/en
Priority to EP03715949A priority patent/EP1476155A4/fr
Priority to CA002476565A priority patent/CA2476565A1/fr
Publication of WO2003061594A2 publication Critical patent/WO2003061594A2/fr
Publication of WO2003061594A3 publication Critical patent/WO2003061594A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés destinés à réduire, à prévenir ou à retarder le développement de tolérance à certains médicaments qui ciblent les récepteurs couplés à la protéine G (GPCR). Ces procédés sont, en général, mis en oeuvre par co-administration avec le médicament d'un agoniste du GPCR cible du médicament qui favorise l'endocytose du récepteur ciblé. Ils sont particulièrement utiles pour des médicaments qui ciblent les récepteurs opioïdes, par exemple la morphine. Cette invention concerne également des compositions comprenant un médicament et un agoniste qui permettent de prévenir de façon avantageuse le développement de tolérance au médicament que peut développer un médicament lorsqu'il est administré seul.
PCT/US2003/002061 2002-01-23 2003-01-22 Procedes et compositions destines a reduire le developpement de tolerance au medicament et/ou de dependance physique WO2003061594A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003219680A AU2003219680A1 (en) 2002-01-23 2003-01-22 Methods and compositions for reducing the development of drug tolerance and/or physical dependence
EP03715949A EP1476155A4 (fr) 2002-01-23 2003-01-22 Procedes et compositions destines a reduire le developpement de tolerance au medicament et/ou de dependance physique
CA002476565A CA2476565A1 (fr) 2002-01-23 2003-01-22 Procedes et compositions destines a reduire le developpement de tolerance au medicament et/ou de dependance physique

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35144202P 2002-01-23 2002-01-23
US35146602P 2002-01-23 2002-01-23
US60/351,466 2002-01-23
US60/351,442 2002-01-23

Publications (2)

Publication Number Publication Date
WO2003061594A2 WO2003061594A2 (fr) 2003-07-31
WO2003061594A3 true WO2003061594A3 (fr) 2003-09-25

Family

ID=27616803

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/002061 WO2003061594A2 (fr) 2002-01-23 2003-01-22 Procedes et compositions destines a reduire le developpement de tolerance au medicament et/ou de dependance physique

Country Status (5)

Country Link
US (1) US20040024005A1 (fr)
EP (1) EP1476155A4 (fr)
AU (1) AU2003219680A1 (fr)
CA (1) CA2476565A1 (fr)
WO (1) WO2003061594A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882944A (en) * 1993-06-23 1999-03-16 The Regents Of The University Of California Methods for G protein coupled receptor activity screening
US6270979B1 (en) * 1993-06-23 2001-08-07 The Regents Of The University Of California Methods for anti-addictive narcotic analgesic treatments

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416871A (en) * 1978-07-10 1983-11-22 The United States Of America As Represented By The Department Of Health And Human Services Inhibition by peptides of tolerance to and physical dependence on morphine
US4315936A (en) * 1979-12-17 1982-02-16 Ortho Pharmaceutical Corporation Analgesic composition
DE3600905A1 (de) * 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US6127352A (en) * 1988-02-01 2000-10-03 Uribe; Jose R. Pharmaceutical compositions with analgesics containing codeine
IT1224250B (it) * 1988-06-10 1990-09-26 Acraf Associzione del depiprazolo con la morfina
US5057519A (en) * 1990-06-11 1991-10-15 Bristol-Myers Squibb Company 5-HT3 antagonists: use in reducing opiate tolerance
IT1249034B (it) * 1990-06-29 1995-02-11 Fidia Spa Impiego del monosialoganglioside gm1 e del suo derivato estere interno per impedire l'instaurarsi della tolleranza nell'uomo all'effetto analgesico della morfina e analoghi
US5908832A (en) * 1991-10-07 1999-06-01 University Of Houston - Clearlake Peptide analog
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
AUPN603895A0 (en) * 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
DK1003494T3 (da) * 1997-01-22 2007-07-16 Cornell Res Foundation Inc (d)-metadon, et ikke-opioidt analgetikum
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
DE19901687B4 (de) * 1999-01-18 2006-06-01 Grünenthal GmbH Opioide Analgetika mit kontrollierter Wirkstofffreisetzung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882944A (en) * 1993-06-23 1999-03-16 The Regents Of The University Of California Methods for G protein coupled receptor activity screening
US6270979B1 (en) * 1993-06-23 2001-08-07 The Regents Of The University Of California Methods for anti-addictive narcotic analgesic treatments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1476155A4 *

Also Published As

Publication number Publication date
EP1476155A4 (fr) 2009-10-28
EP1476155A2 (fr) 2004-11-17
WO2003061594A2 (fr) 2003-07-31
CA2476565A1 (fr) 2003-07-31
AU2003219680A1 (en) 2003-09-02
US20040024005A1 (en) 2004-02-05

Similar Documents

Publication Publication Date Title
WO2007008752A3 (fr) Compositions pharmaceutiques a liberation prolongee pour medicaments tres solubles dans l'eau
WO2007120270A3 (fr) Antagonistes de récepteur du glucagon, procédés de préparation et utilisations thérapeutiques
WO2006086488A3 (fr) Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiques
WO2007106181A3 (fr) Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques
WO2008057579A3 (fr) Formes dosifiées et co-administration d'un agoniste opioïde et d'un antagoniste opioïde
WO2006071740A3 (fr) Compositions renfermant un modulateur des recepteurs 5ht2c et procedes d'utilisation correspondants
AU2003246627A1 (en) Morphinan derivatives the quaternary ammonium salts thereof substituted in position 14, method for production and use thereof
WO2006082588A3 (fr) Procede et dispositif d'administration ophtalmique d'ingredients pharmaceutiquement actifs
PL1957484T3 (pl) Antagoniści receptora glukagonu, wytwarzanie i zastosowanie w lecznictwie
WO2005034859A3 (fr) Formulations d'opioides a liberation prolongee et methode d'utilisation des formulations
WO2004104018A3 (fr) Compostions d'administration de peptide yy de d'agonistes pyy
WO2007114855A3 (fr) Antagonistes du récepteur du glucagon, préparation et utilisations thérapeutiques
UA86621C2 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
WO2008063301A3 (fr) Compositions pharmaceutiques
WO2005117895A3 (fr) Compositions contenant de la meloxicame
WO2003061594A3 (fr) Procedes et compositions destines a reduire le developpement de tolerance au medicament et/ou de dependance physique
AU2003297561A1 (en) Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
WO2006047392A3 (fr) Synergie entre nicotine et opioides a des fins d'analgesie
WO2004026837A3 (fr) Antagonistes du recepteur h3 d'histamine, preparation et applications therapeutiques
Coop et al. The future of opioid analgesics
GB0325605D0 (en) Combination of organic compounds
AU2003291608A1 (en) A method of drug screening to select agonists or antagonists of g protein coupled receptors (gpcr).
EP1842555A4 (fr) Inhibiteur de developpement de tolerance destine a un agent analgesique narcotique
WO2007030770A3 (fr) Recepteurs de l'endotheline utilises dans le sevrage de la morphine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003715949

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2476565

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2003715949

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载